Previous close | 15.61 |
Open | 16.39 |
Bid | 15.30 |
Ask | 19.00 |
Strike | 70.00 |
Expiry date | 2024-11-15 |
Day's range | 16.39 - 16.39 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that its investigational OmniaSecure™ defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivotal Trial. Late breaking results were presented at Heart Rhythm 2024 and simultaneously published in the journal Heart Rhythm. Worldwide, the OmniaSecure defibrillation lead is investigational
Medtronic (MDT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Earnings preview of key companies reporting this week and what to look out for.